All In MedTech

Device Trial Radar · NCT07926854

Unipolar Voltage-Guided Substrate Modification Plus Pulsed Field Ablation Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation

Unipolar Voltage-Guided Individualized Substrate Modification Combined With Pulsed Field Ablation-Based Pulmonary Vein Isolation Versus Pulmonary Vein Isolation Alone in Persistent Atrial Fibrillation: A Multicenter, Randomized, Open-Label, Superiority Trial

Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingRandomized with 294 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

294

Planned (sponsor's estimate)

Start

Nov 2026

Primary completion

Dec 2028

Study completion Dec 2029

Sponsor

Lead sponsor
China National Center for Cardiovascular DiseasesGovernment (non-federal)
Sponsor type
Government (non-federal)
Collaborators
Sir Run Run Shaw Hospital; Guangdong Provincial People's Hospital; Affiliated Hospital of Hebei University; Shanxi Cardiovascular Hospital; The University of Hong Kong-Shenzhen Hospital; The Second Hospital of Hebei Medical University; Second Affiliated Hospital of Xi'an Jiaotong University; The Second Affiliated Hospital of Chongqing Medical University
First posted
Nov 9, 2026

More device trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable (typical for device studies)
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated device
No
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

UNI-PFA is a multicenter, randomized, open-label, superiority trial evaluating whether adding unipolar voltage-guided individualized substrate modification to pulsed field ablation (PFA)-based pulmonary vein isolation (PVI) improves outcomes in patients with persistent atrial fibrillation and a left atrial low-voltage area (LVA) burden of at least 10% of the post-PVI left atrial surface area. Participants are randomized 1:1 to PFA-PVI plus individualized substrate modification (homogenization, box isolation, linear ablation, or a combination) or PFA-PVI alone. The primary endpoint is treatment success at 12 months, defined as freedom from documented atrial fibrillation, atrial tachycardia, or atrial flutter lasting more than 30 seconds after a 90-day blanking period while off class I/III antiarrhythmic drugs. Follow-up includes 14-day continuous ECG patch monitoring at 3, 6, and 12 months, symptom-triggered single-lead ECG, and quality-of-life assessments.

Conditions

  • Atrial Fibrillation (AF)

Interventions

  • VARIPULSE Pulsed Field Ablation SystemDevice

    Pulsed field ablation catheter and generator used to perform pulmonary vein isolation in both study arms.

  • Pulmonary Vein IsolationProcedure

    Pulsed field ablation-based pulmonary vein antral isolation with confirmation of entrance and exit block in all pulmonary veins; performed in both arms.

  • Individualized Substrate ModificationProcedure

    Unipolar voltage-guided individualized substrate modification selected according to low-voltage area location, including homogenization, box isolation, linear ablation, or a combination. Performed in the experimental arm only.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treatment Success at 12 Months After the Index Ablation ProcedureTime frame: 12 months after the index ablation procedure

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Fuwai Hospital, Chinese Academy of Medical Sciences

    Beijing, Beijing Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.